Effects of probiotic in generalized anxiety disorder

Effect of probiotics on BDNF, neuropeptide y plasma and serum HS-CRP in patients with generalized anxiety disorder

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20090901002394N39

Enrollment

Registered

2018-10-26

Start date

2017-05-05

Completion date

Unknown

Last updated

2019-01-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Generalized anxiety disorde. Anxiety that is generalized and persistent but not restricted to, or even strongly predominating in, any particular environmental circumstances (i.e. it is "free-floating"). The dominant symptoms are variable but include complaints of persistent nervousne

Interventions

Intervention 1: Intervention group: sertraline plus probiotic supplement Contain Bifidobacterium Longom, Bifidobacterium bifidum, Bifidobacterium lactis, Lactobacillus acidophilus(18×109 CFU) and smal

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: DSM-V diagnosed of GAD Adults between 18 and 65 years old Willing to participate.

Exclusion criteria

Exclusion criteria: Having illness including liver disease and kidney disease, diabetes, immune deficiency, etc Having psychological illnesses including psychosis, Suicidal ideation, bipolar disorder and major depression People who are expected to have limited partnerships such as forgetfulness and pregnancy Taking any medication in the previous 1 month Taking any medication related to psychiatric diseases including antidepressants, antipsychotics, etc. (maximum of two times per week) and antibiotics in the previous 1 month Taking any supplement including probiotic supplement, fiber, prebiotics, omega-3, vitamins and minerals in the previous 1 month; Consumption of fermented foods (except yogurt), such as sour cream, acidophilus milk, kefir and some cheeses such as blue vein cheese or Swiss cheese in the previous 1 month substance abuse The compliance less than 80%.

Design outcomes

Primary

Measure	Time frame
BDNF. Timepoint: At baseline, after 2 month. Method of measurement: Blood test.;Hs-crp. Timepoint: At baseline, after 2 month. Method of measurement: Blood test.;Neuropeptide y. Timepoint: At baseline, after 2 month. Method of measurement: Blood test.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMahnaz Reisian

Iran University of Medical Sciences

Reisian2012@gmail.com+98 21 8670 4805

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026